文献速递乳腺癌

竞争性死亡风险对早期乳腺癌辅助内分泌治疗试验中复发估计的影响

Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R.
PubMed 文献 · Eur J Cancer · 2021-04-11

该研究基于MA.27、MA.17和MA.17R三项辅助内分泌治疗试验,比较Kaplan-Meier法与竞争风险法对无病生存(DFS)和远处复发无生存(DRFS)的估计差异。结果显示竞争风险法估计的DFS和DRFS事件比例更低,且差异随随访延长而增大;绝对治疗获益相似或略低。作者认为长期随访中竞争风险法可能更适用于估计早期激素敏感性乳腺癌的复发风险。

要点

  • 竞争风险法较Kaplan-Meier法低估DFS和DRFS事件比例,差异随随访时间延长而增大。
  • 竞争风险法下绝对治疗获益与Kaplan-Meier法相似或略低。
  • 非乳腺癌死亡在老年、低危和随访较长的患者中更常见。

核心结论

  • 与Kaplan-Meier法相比,竞争风险分析得到的DFS和DRFS事件估计更低,绝对治疗获益相似或略低。
  • 在长期随访中,估计早期激素敏感性乳腺癌的未来复发风险时,竞争风险法可能优于Kaplan-Meier法。

研究设计与样本

  • 基于MA.27、MA.17和MA.17R三项辅助内分泌治疗试验数据的二次分析,每项试验单独分析。
  • 比较Kaplan-Meier法与竞争风险法(累积发生率函数,以非乳腺癌死亡为竞争风险)对DFS和DRFS的估计。

主要发现

  • 非乳腺癌死亡在年龄较大、乳腺癌风险较低和随访时间较长的参与者中更常见。
  • 竞争风险分析中DFS或DRFS事件比例低于传统分析,且差异随随访时间延长而增大。
  • 竞争风险分析中绝对治疗获益与Kaplan-Meier法相似或略低。

临床怎么用

  • 在早期激素敏感性乳腺癌的长期随访中,评估复发风险时可考虑采用竞争风险法而非Kaplan-Meier法。
  • 解读辅助内分泌治疗试验的DFS和DRFS数据时,需注意竞争性死亡风险对估计值的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many women diagnosed with early-stage hormone-sensitive breast cancer die of causes other than their breast cancer. These competing risks can create challenges in analysing and clearly communicating data on risk of breast cancer recurrence or death. Here, we quantify the impact of competing risks on estimates of disease recurrence and benefit from therapy. PATIENTS AND METHODS: Using data from the MA.27, MA.17 and MA.17R trials of adjuvant endocrine therapy in early breast cancer, we compared Kaplan-Meier (KM) and competing risk methods for disease-free survival (DFS) and distant recurrence-free survival (DRFS). Each trial was analysed separately. In KM analyses, participants were censored at the time of non-breast cancer death. Competing risk analyses comprised cumulative incidence functions in which non-breast cancer death was a competing risk. RESULTS: Non-breast cancer deaths were observed more often in older participants, in those with lower risk of breast cancer and after longer follow-up. Compared with conventional analyses, estimates of the proportion of participants with DFS or DRFS events were lower in competing risk analyses, with this difference increasing over the course of follow-up. The absolute treatment benefit was similar or modestly lower in competing risk analyses. CONCLUSION: Compared with KM methods, competing risk analyses result in lower estimates of DFS and DRFS events and similar or modestly lower absolute benefit from experimental endocrine therapy. Over a long time horizon, competing risk methods may be preferable to KM methods when estimating future risk of recurrence in early-stage hormone-sensitive breast cancer. CLINICAL TRIALS REGISTRATION: Clinicaltrials.gov; NCT00003140, NCT00754845, NCT00066573.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ethier JL, Anderson GM, Austin PC, et al. Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. Eur J Cancer. 2021. PMID: 33853037. doi:10.1016/j.ejca.2021.02.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。